Merck's Keytruda fails as monotherapy in breast cancer study

Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the treatment as a monotherapy in patients with an aggressive type of breast cancer.